Search

everythinglearnresearchcommunity

for

Search:↓

Blocking Wnt signaling in young mice causes thymus shrinkage and cell loss, but recovery is possible when the block is removed.

Men with common hair loss may have a higher risk of heart disease and diabetes, and should be checked for these conditions.

Immune cells affect hair growth and could lead to new hair loss treatments.

Copeptin and cortisol levels are higher in alopecia areata patients, suggesting they could help diagnose and manage the condition.

Asthma may increase the risk of alopecia areata.

Vitiligo is a systemic disease with psychological effects, and new treatments focus on personalized care.

Upadacitinib can effectively regrow hair in alopecia areata patients without worsening sarcoidosis.

High levels of HSP70 and IL-15 are linked to more severe alopecia areata.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

A personalized treatment combining traditional and new therapies may improve hair loss outcomes in alopecia areata.

Arg1+ macrophages may play a role in causing alopecia areata.

The excimer laser may help hair regrow in alopecia areata patients.

IL-17 is more important than IFN-γ in causing severe hair loss in chronic alopecia areata.

Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.

JAK inhibitors show promise for treating alopecia areata but have serious side effects.

Blocking LFA-1 prevents hair loss in mice.

New treatments like JAK inhibitors show promise for reversing alopecia areata.

Targeting JAK-STAT1 can reduce inflammation and promote hair growth in conditions linked to EGFR deficiency.

Oral lichen planus is a chronic disease causing mouth discomfort and sometimes needs immunosuppressive treatment.

Childhood Alopecia Areata causes hair loss and requires varied treatments, with psychological support being crucial.

Copper may protect against alopecia areata, while certain inflammatory markers increase risk.

RSPO1 could help create new diabetes treatments by increasing pancreatic β cells.

JAK inhibitors have therapeutic potential but pose significant risks, requiring careful monitoring.

Alopecia areata affects about 1.93% of people worldwide, with more women affected than men.

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

Special cells can help regrow hair in alopecia areata.

Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.

Targeting regulatory T cells may help treat age-related diseases.

Hair follicles are key to treating vitiligo and alopecia areata, but challenges exist.

Higher CRHR1 levels in AA patients lead to increased inflammation.